News
BHVN
42.16
-4.25%
-1.87
BUZZ-U.S. STOCKS ON THE MOVE-Ibotta, Blackstone, US health insurers
Wall Street's main stock indexes gained on Thursday. Dow Jones Industrial Average was up 0.11% at 37,793.34. Top three S&P 500 percentage gainers: Estee Lauder, United Airlines, Genuine Parts. Top two Nasdaq percentage losers: Las Vegas Sands and Tesla.
Reuters · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Ally Financial, Zscaler, Las Vegas Sands
Dow Jones Industrial Average was up 0.52% on Thursday. The benchmark S&P 500 and the Nasdaq were subdued as higher Treasury yields pressured equities. Zscaler, Las Vegas Sands, 23andMe and Ally Financial were among the day's top stocks.
Reuters · 6h ago
BUZZ-Biohaven dips after $230 mln equity raise
Biohaven's BHVN.N shares down 2.6% at $42.90 before the bell after follow-on priced. Biotech firm announces $230 mln equity raise. Firm's stock has roughly tripled over the past 12 months. Company is developing an experimental inflammatory disease drug.
Reuters · 9h ago
BIOHAVEN LTD - PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5,609,757 OF ITS COMMON SHARES AT A PRICE TO PUBLIC OF $41.00 PER SHARE
Reuters · 13h ago
BIOHAVEN LTD - FILES FOR OFFERING OF ITS COMMON SHARES OF UP TO $200 MLN
Reuters · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 3d ago
BUZZ-Biohaven provides update for its inflammatory disease drug; stock falls
Biohaven's BHVN.N shares fall 12.9% to $46.24. Company provides update on ongoing early stage study of its inflammatory disease drug. Drug's starting dose of 10 milligrams is lower than anticipated. Drug is safe and well tolerated, company says.
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Dow Jones Industrial Average was up 0.36% at 38,119.77. Goldman Sachs boosted by robust gains. Top three S&P 500 percentage gainers: M&T Bank, Centene, Snap One. Apple down 0.6% after falling in premarket trading.
Reuters · 3d ago
BIOHAVEN SHARES DOWN 14.8% AFTER CO PROVIDES UPDATE ON EARLY-STAGE STUDY FOR ITS INFLAMMATORY DISEASE DRUG
Reuters · 3d ago
Weekly Report: what happened at BHVN last week (0408-0412)?
Weekly Report · 3d ago
BIOHAVEN SHOWCASES INNOVATIVE NEUROSCIENCE PORTFOLIO WITH 20 PRESENTATIONS AT THE 2024 AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING AND PROVIDES OTHER BUSINESS UPDATES
Reuters · 5d ago
Weekly Report: what happened at BHVN last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at BHVN last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at BHVN last week (0311-0315)?
Weekly Report · 03/18 09:11
Weekly Report: what happened at BHVN last week (0304-0308)?
Weekly Report · 03/11 09:11
Weekly Report: what happened at BHVN last week (0226-0301)?
Weekly Report · 03/04 09:11
U.S. RESEARCH ROUNDUP-Broadcom, New York Community Bancorp, TopBuild
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Broadcom, New York Community Bancorp, and TopBuild are among the companies. Analysts raise target prices on several companies, including Bath & Body Works and Bath and Body Works.
Reuters · 03/01 06:50
Weekly Report: what happened at BHVN last week (0219-0223)?
Weekly Report · 02/26 09:12
Weekly Report: what happened at BHVN last week (0212-0216)?
Weekly Report · 02/19 09:13
Weekly Report: what happened at BHVN last week (0205-0209)?
Weekly Report · 02/12 09:12
More
Webull provides a variety of real-time BHVN stock news. You can receive the latest news about Biohaven through multiple platforms. This information may help you make smarter investment decisions.
About BHVN
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.